The role of hydroxychloroquine in COVID-19: Where do we stand?

被引：0

作者：

Anjana, Ranjit Mohan ^{[1
,2
]}

Sastry, Nadiminty Ganapathi ^{[1
]}

Ramuu, Muthu ^{[1
]}

Gupta, Prasanna Kumar ^{[1
]}

Shalini, Jaggi ^{[1
]}

Srivastava, Brijendra Kumar ^{[1
]}

Kocherlakota, Chaithanya Murthy ^{[1
]}

Nandan, Tata Sameer ^{[1
]}

Praveen, Gangadhara ^{[1
]}

Nair, Jyotish ^{[1
]}

Philips, Routray ^{[1
]}

Mohan, Viswanathan ^{[1
,2
]}

Unnikrishnan, Ranjit ^{[1
,2
]}

机构：

[1] Dr Mohans Diabet Special Ctr, Dept Diabetol, Chennai, Tamil Nadu, India

[2] Madras Diabet Res Fdn, Dept Diabetol, Chennai, Tamil Nadu, India

来源：

JOURNAL OF DIABETOLOGY | 2020年 / 11卷 / 02期

关键词：

Coronavirus disease 2019; hydroxychloroquine; treatment; CHLOROQUINE;

D O I：

10.4103/JOD.JOD_33_20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hydroxychloroquine (HCQ) is a drug, which has long been used in the treatment of malaria, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome. Recently with the COVID-19 pandemic hitting the world, there have been studies suggesting that hydroxychloroquine may be useful both in the prevention and the treatment of COVID-19, although the evidence so far has been conflicting. This article reviews the available evidence for the use of hydroxychloroquine in COVID-19 and also mentions some of the ongoing trials in this field.

引用

页码：65 / 70

页数：6

共 50 条

[31] COVID-19 vaccines: where we stand and challenges ahead
Forni, Guido
Mantovani, Alberto
[J]. CELL DEATH AND DIFFERENTIATION, 2021, 28 (02): : 626 - 639
[32] COVID-19 vaccines: where we stand and challenges ahead
Guido Forni
Alberto Mantovani
[J]. Cell Death & Differentiation, 2021, 28 : 626 - 639
[33] B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?
Mehta, Puja
Porter, Joanna C.
Chambers, Rachel C.
Isenberg, David A.
Reddy, Venkat
[J]. LANCET RHEUMATOLOGY, 2020, 2 (10): : E589 - E590
[34] Role of electronic devices in obtaining informed consent for critically ill COVID-19 patients: Where do we stand?
Sarkar, Soumya
Anand, Rahul K.
Ray, Bikash R.
Baidya, Dalim K.
Maitra, Souvik
[J]. JOURNAL OF ANAESTHESIOLOGY CLINICAL PHARMACOLOGY, 2022, 38 : 137 - 138
[35] Role of electronic devices in obtaining informed consent for critically ill COVID-19 patients: Where do we stand?
Krishnaswamy, Sharath
Surve, Rohini M.
Kamath, Sriganesh
Maitra, Souvik
[J]. JOURNAL OF ANAESTHESIOLOGY CLINICAL PHARMACOLOGY, 2022, 38 (05) : 137 - 138
[36] Myocarditis after RNA-based COVID-19 vaccines: Where do we stand?
Moroni, Francesco
[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 356 : 81 - 82
[37] Noninvasive respiratory support and invasive ventilation in COVID-19 Where do we stand today?
Schroeder, Ines
Irlbeck, Michael
Zoller, Michael
[J]. ANAESTHESIST, 2022, 71 (05): : 333 - 339
[38] Hematology Oncology Patients' Care in a Pandemic Situation of COVID-19: Where Do We Stand?
Ali, Kashif
Wajdi, Mehwish
Al-Quteimat, Osama
[J]. HOSPITAL PHARMACY, 2021, 56 (06) : 622 - 623
[39] Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic?
Falchetti, A.
Mohseni, M.
Tramontana, F.
Napoli, N.
[J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (11) : 2521 - 2524
[40] Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic?
A. Falchetti
M. Mohseni
F. Tramontana
N. Napoli
[J]. Journal of Endocrinological Investigation, 2021, 44 : 2521 - 2524

← 1 2 3 4 5 →